Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSolvonis Therap Regulatory News (SVNS)

Share Price Information for Solvonis Therap (SVNS)

Share Price is delayed by 15 minutes
Get Live Data
0.175    -0.01 (-5.41%)
Bid:
0.17
Ask:
0.18
Spread: 0.01 (5.882%)
Market Cap: £11.91m
SVNS Live PriceLast checked at - London Stock Exchange

Intraday Solvonis Therap Share Chart

Interview with CEO

15 Jan 2025 07:00

RNS Number : 3342T
Solvonis Therapeutics PLC
15 January 2025
 

RNS Reach - non-regulatory announcement

15 January 2025

Solvonis Therapeutics plc("Solvonis Therapeutics" or the "Company")

 

Proactive Investors interview with CEO

 

Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces an interview on Proactive Investors with Anthony Tennyson, CEO of the Company. The interview with Anthony Tennyson can we viewed now at https://www.proactiveinvestors.co.uk/companies/news/1064271/solvonis-therapeutics-ceo-on-name-change-awakn-acquisition-and-2025-priorities.html.

 

Enquiries:

 

Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive DirectorEmail: anthonytennyson@graftpolymer.co.uk and also anthony@solvonis.com

 

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Solvonis Therapeutics plc

 

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the US, UK and key EU markets.

 

For more information, please visit www.graft polymer.co.uk and also www.solvonis.com

 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUGPGUPAPUC
12
Date   Source Headline
16th Apr 20257:00 amRNSFinal Results for the year ended 31 December 2024
10th Apr 20252:00 pmRNSPosting of Circular and Notice of General Meeting
7th Apr 20257:00 amRNSHolding(s) in Company
4th Apr 20257:00 amRNSEngagement of PharmaVentures
26th Mar 20257:00 amRNSPositive progress on European Patent Application
18th Mar 20257:00 amRNSUpdate on AWKN-SDN-14 programme
11th Mar 20259:00 amRNSHolding(s) in Company
11th Mar 20257:00 amRNSAppointment of Non-Executive Director
25th Feb 20257:00 amRNS-RPresentation at PharmaSynergyRx Event
24th Feb 20257:00 amRNSEntry into an Arrangement Agreement with Awakn
30th Jan 202512:00 pmRNS-RProactive Investors interview with Chairman
27th Jan 20257:00 amRNSUpdate on Awakn Life Sciences’ R&D Progress
24th Jan 20257:00 amRNS-RInvestor Presentation
21st Jan 20252:29 pmRNS-RProactive Investors interview with CEO
21st Jan 20257:00 amRNSUpdate on FDA Pre-IND Meeting for Awakn
15th Jan 20257:00 amRNS-RInterview with CEO
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.